
What is claimed is

1. A compound represented by formula (II), an optical isomer thereof or a pharmacologically acceptable salt thereof,



(II)

,

wherein, ring A and ring B are independently 3- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl; and the 3- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R;

R_1, R_2, R_3 and R_4 are each independently selected from CN, halogen, C_{1-6} alkyl and C_{1-6} alkoxy, and the C_{1-6} alkyl and C_{1-6} alkoxy are optionally substituted by 1, 2 or 3 R;

X is selected from C(R) and N;

T_1, T_2, T_3 and T_4 are each independently selected from C(R) and N;

T_5 is selected from -(C=O)- and $-CH_2-$;

L_2 is O, S, NH, C(=O), S(=O), $S(=O)_2$, C_{1-6} alkyl, -C_{1-6} alkyl-O-, -C_{1-3} alkyl-NH-, -O-C_{1-6} alkyl-O-, or -O-C_{1-6} alkyl-O-C_{1-6} alkyl-; wherein the C_{1-6} alkyl, -C_{1-6} alkyl-O-, -C_{1-3} alkyl-NH-, -O-C_{1-6} alkyl-O-, or -O-C_{1-6} alkyl-O-C_{1-6} alkyl are optionally substituted by 1, 2 or 3 R_L;

R_L are each independently selected from H, halogen, OH, NH_2, CN, , C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{1-6} alkyl-C(=O)-, C_{1-6} alkoxy, C_{1-6} alkylthio and C_{1-6} alkylamino;

R is selected from H, F, Cl, Br, I, OH and C_{1-6} alkyl;

R_5 is selected from H, halogen and C_{1-6} alkyl;

the 3- to 8-membered heterocycloalkyl, 3- to 10-membered heterocycloalkyl, 5- to 6-membered heteroaryl or 5- to 9-membered heteroaryl contains 1, 2 or 3 heteroatoms independently selected from the group consisting of -O-, -NH-, -S-, and N.

2. The compound, the optical isomer thereof, or the pharmacologically acceptable salt

thereof as claimed in claim 1, wherein

ring A and ring B are independently 3- to 8-membered heterocycloalkyl or 5- to 6-membered heteroaryl;

R_1, R_2, R_3 and R_4 are each independently selected from the group consisting of CN, halogen, C_{1-6} alkyl and C_{1-6} alkoxy;

X is C(R);









T_1, T_2, T_3 and T_4 are each independently C(R) or N;

T_5 is -(C=O)-;

L_2 is C_{1-6} alkyl, -C_{1-6} alkyl-O-, -C_{1-3} alkyl-NH-, -O-C_{1-6} alkyl-O-, or -O-C_{1-6} alkyl-O-C_{1-6} alkyl;

R_5 is H, halogen, or C_{1-6} alkyl;








the 3- to 8-membered heterocycloalkyl, 3- to 10-membered heterocycloalkyl, 5- to 6-membered heteroaryl or 5- to 9-membered heteroaryl contains 1 or 2 heteroatoms independently selected from the group consisting of -NH- and N.

3. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1 or 2, wherein, the moiety  is , , , , , , or .

4. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1 or 2, wherein, R is selected from H, halogen, OH, methyl, ethyl, n-propyl, isopropyl.

5. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof, as claimed in claim 1 or 2, wherein, R_1 and R_2 are each independently selected from CN, halogen, CH_3O- and -CF_3.

6. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1 or 2, wherein, R_3 and R_4 are each independently selected from methyl, ethyl, n-propyl and isopropyl.

7. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1 or 2, wherein, the moiety  is selected from , , , ,  and .

8. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, L_2 is O, S, NH, C(=O), S(=O), $S(=O)_2$, C_{1-3} alkyl, -C_{1-4} alkyl-O-, -C_{1-3} alkyl-NH-, -O-C_{1-4} alkyl-O-, or -O-C_{1-3} alkyl-O- C_{1-3} alkyl-; wherein the C_{1-3} alkyl, -C_{1-4} alkyl-O-, -O-C_{1-4} alkyl-O-, -C_{1-3} alkyl-NH-, and -O-C_{1-3} alkyl-O- C_{1-3} alkyl- are optionally substituted by 1, 2 or 3 R_L.

9. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof, as claimed in claim 1 or 8, wherein, the R_L are each independently selected from H, halogen, OH, NH_2, CN, , C_{1-3} alkyl, C_{3-6} cycloalkyl, C_{1-3} alkyl-C(=O)-, C_{1-3} alkoxy, C_{1-3} alkylthio, and C_{1-3} alkylamino.


10. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, L_2 is C_{1-3} alkyl-, -O-C_{1-4} alkyl-, -C_{1-3} alkyl-NH-, -O-C_{1-4} alkyl-O-, and -O-C_{1-3} alkyl-O-C_{1-3} alkyl-; wherein the C_{1-3} alkyl, -O-C_{1-4} alkyl-, -C_{1-3} alkyl-NH-, -O-C_{1-4} alkyl-O- or -O-C_{1-3} alkyl-O-C_{1-3} alkyl- are optionally substituted by 1, 2 or 3 R_L.

11. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, L_2 is -CH_2-, -CH_2CH_2-, -$CH_2CH_2CH_2$-, or -$CH(CH_3)$-.



12. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, ring A and ring B are independently 4- to 6-



membered heterocycloalkyl or 5- to 6-membered heteroaryl; wherein and the 4- to 6-membered heterocycloalkyl or 5- to 6-membered heteroaryl is optionally substituted by 1, 2 or 3 R.




















13. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, ring A is azetidinyl, piperidinyl, piperazinyl, pyrazolyl, or tetrahydropyrrolyl.


14. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, ring A is , , or .





15. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, ring B is morpholinyl, piperazinyl, tetrahydropyrrolyl, piperidinyl, azetidinyl, or piperazine-2-ketonyl.

16. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, ring B is , , or .

17. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1, wherein, the moiety  is selected from .












,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,










and

.

18. The compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in claim 1 or 2, wherein, the moiety  is selected from ,  and .

19. The compound, the optical isomer thereof, or the pharmacologically acceptable salt












thereof as claimed in claim 1, wherein the compound is:










,

,

,

,

,

,

,

,

,

.


,

,

,

,

,

,

,

,

,


,

,



,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

or .


20. The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the compound has the formula:

.


21. The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the compound has the formula:

.


22. The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the compound has the formula:



23. The compound or the pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the compound has the formula:



24. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound has the formula:



25. Use of the compound, the optical isomer thereof or the pharmacologically acceptable salt thereof as claimed in any one of claims 1 to 24 in the manufacture of a medicament for preventing and/or treating cancer.

26. The use as claimed in claim 25, wherein the cancer is prostate cancer.

27. The use as claimed in claim 25, wherein the cancer is breast cancer.

28. Use of the compound, the optical isomer thereof, or the pharmacologically acceptable salt thereof as claimed in any one of claims 1 to 24 in the manufacture of a medicament for treating Kennedy's disease.